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Abstract. Purpose: Tetrahydrobiopterin (BH4) is an es-
sential co-factor for the synthesis of nitric oxide (NO),
and BH4 deficiency may cause impaired NO synthase
(NOS) activity. We studied whether BH4 deficiency con-
tributes to the coronary microcirculatory dysfunction ob-
served in patients with hypercholesterolaemia. 
Methods: Myocardial blood flow (MBF; ml min−1 g−1)
was measured at rest, during adenosine-induced
(140 µg kg−1 min−1 over 7 min) hyperaemia (mainly non-
endothelium dependent) and immediately after supine bi-
cycle exercise (endothelium-dependent) stress in ten heal-
thy volunteers and in nine hypercholesterolaemic subjects
using 15O-labelled water and positron emission tomogra-
phy. Measurements were repeated 60 min later, after in-
travenous infusion of BH4 (10 mg kg−1 body weight over
30 min). Adenosine-induced hyperaemic MBF is consid-
ered to represent (near) maximal flow. Flow reserve utili-
sation was calculated as the ratio of exercise-induced to
adenosine-induced hyperaemic MBF and expressed as
percent to indicate how much of the maximal (adenosine-
induced) hyperaemia can be achieved by bicycle stress. 
Results: BH4 increased exercise-induced hyperaemia in
controls (2.96±0.58 vs 3.41±0.73 ml min−1 g−1, p<0.05)
and hypercholesterolaemic subjects (2.47±0.78 vs
2.70±0.72 ml min−1 g−1, p<0.01) but had no influence on
MBF at rest or during adenosine-induced hyperaemia in
controls (4.52±1.10 vs 4.85±0.45 ml min−1 g−1, p=NS) 
or hypercholesterolaemic subjects (4.86±1.18 vs 4.53±
0.93 ml min−1 g−1, p=NS). Flow reserve utilisation re-
mained unchanged in controls (70±17% vs 71±19%,
p=NS) but increased significantly in hypercholestero-
laemic subjects (53±15% vs 66±14%, p<0.05). 
Conclusion: BH4 restores flow reserve utilisation of the
coronary microcirculation in hypercholesterolaemic sub-
jects, suggesting that BH4 deficiency may contribute to
coronary microcirculatory dysfunction in hypercholes-
terolaemia.
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Introduction
In hypercholesterolaemic patients, endothelial-mediated
dilation of angiographically normal coronary arteries is
impaired [1, 2]. This endothelial dysfunction is, at least in
part, reversible by L-arginine infusion and treatment with
lipid-lowering drugs or can be compensated by the effect
of calcium channel blockers on vascular smooth muscle
cells [3]. From in vitro results, endothelial dysfunction
has been attributed to attenuation of nitric oxide (NO) re-
lease and/or superoxide anion production induced by oxi-
dised low-density lipoprotein (LDL) cholesterol. In stud-
ies with positron emission tomography (PET), a reduction
in coronary flow reserve (CFR) has been documented in
hypercholesterolaemic asymptomatic subjects with nor-
mal coronary arteries and mainly associated with the
LDL lipid fraction rather than with total cholesterol levels
[4]. CFR and flow-mediated dilation are impaired owing
to reduced NO production or release [5, 6].
NO synthase (NOS) produces both NO and, under
certain conditions, superoxide anion (O•). A physiologi-
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cal balance between NO and O• requires an adequate
concentration of tetrahydrobiopterin (BH4), an essential
co-factor of the NOS complex. Decreased BH4 concen-
tration in endothelial cells of patients with hypercholes-
terolaemia has been associated with increased O• produc-
tion and endothelial dysfunction [7]. Furthermore, im-
provement of coronary endothelial function has been
demonstrated after intracoronary infusion of BH4 in hy-
percholesterolaemic patients [8]. It remains unclear,
however, whether these phenomena extend to the coro-
nary microcirculation and, thus, to the regulation of
myocardial blood flow (MBF).
The aim of this study was to examine whether sys-
temic BH4 administration restores endothelial-dependent
regulatory mechanisms of MBF in asymptomatic sub-
jects with hypercholesterolaemia. To stimulate endotheli-
al NOS (eNOS) in a shear stress-dependent manner, bi-
cycle exercise was used, while adenosine, which exerts
its effect largely independently of NO, served as control.
Materials and methods
Study population
Ten healthy males (mean age 25±3 years) and nine subjects with
hypercholesterolaemia (mean age 54±8 years) were included in
the study. The baseline characteristics are summarised in Table 1.
Both groups had no history of and low clinical probability for cor-
onary artery disease. Entry criteria included normal heart rate,
blood pressure and electrocardiogram (ECG). None of the subjects
had any cardiovascular risk factors except for hypercholestero-
laemia in the hypercholesterolaemic group, and all subjects were
free of cardiovascular symptoms. Lipid profile was normal in all
volunteers (total cholesterol 4.4±0.4 mmol l−1, ratio of total to
HDL cholesterol 3.3±0.5) and abnormal in the hypercholestero-
laemic group according to the inclusion criteria (total cholesterol
8.7±2.1 mmol l−1, ratio of total to HDL cholesterol 6.7±2.9). All
subjects refrained from ingesting caffeinated beverages or food for
24 h before the study. None of the hypercholesterolaemic subjects
had been on statins for at least 6–8 weeks.
Study protocol
With the subject’s feet attached to a bicycle ergometer (model 380
B, Siemens-Elema AG, Switzerland), MBF was measured at rest
and repeated during adenosine-induced hyperaemia after a 10-min
period to allow for decay of 15O radioactivity. Adenosine was in-
fused for 7 min at 140 µg per kg body weight per minute accord-
ing to standard practice. Three minutes after the start of the adeno-
sine infusion, the hyperaemic MBF measurement was started. Af-
ter a 10-min interval, exercise was started at 50–75 W, and work-
load was increased in increments of 25 W min−1 to reach 70% of
the predicted value for upright bicycle exercise within a compara-
ble time period in all subjects. MBF measurement was performed
immediately after the end of exercise as recently documented [9,
10]. This was followed by an intravenous BH4 infusion
(10 mg kg−1) over 30 min and by an additional break of 30 min to
allow for the maximal vasodilating effect of BH4 [11]. During this
time, a 20-min transmission scan was acquired for the purpose of
attenuation correction of all emission scans. Sixty minutes after
starting the BH4 infusion, a repeat series of three MBF measure-
ments was performed using the same protocol as was employed at
baseline. The BH4 dose of 10 mg kg−1 was chosen according to
previous dose-finding studies in which this dose had proved safe
and effective in the coronary circulation of healthy volunteers
[11].
Blood pressure was continuously monitored by a Finapress BP
Monitor (BOC, Inc, Englewood, CO, USA) and recorded at base-
line and every minute during adenosine administration as well as
at each exercise level and during 10 min of recovery. The ECG
was monitored continuously throughout the procedure and a 12-
lead ECG was recorded at identical times as blood pressure.
Repeatability substudy
In an additional subgroup of five hypercholesterolaemic subjects
(total cholesterol 7.0±0.9 mmol l−1, ratio of total to HDL choles-
terol 6.34±0.74), saline was infused instead of BH4 to assess the
repeatability of the measurements.
Image acquisition
MBF was assessed in the PET Center of the University Hospital in
Zurich on a GE advance positron emission tomograph (GE Medi-
cal Systems, Milwaukee, WI, USA). Starting after the background
frame, 15O-water (500–700 MBq) was injected as an intravenous
bolus over 20 s at an infusion rate of 10 ml min−1 to assess MBF.
The line was then flushed for another 2 min. The dynamic image
sequences were: 14×5 s, 3×10 s, 3×20 s and 4×30 s.
Image processing
The obtained sinograms were corrected for attenuation and recon-
structed on a SUN workstation (Sun Microsystems, Mountain
View, CA) using standard reconstruction algorithms. Images were
transferred to a transtec 2200 PC (transtec Computer AG, Bulach,
Switzerland) and analysed with the PMOD (PMOD Technologies
GmbH, www.pmod.ch) software package designed and validated
at our institution [9, 12]. Myocardial images were generated di-
rectly from the dynamic 15O-water study by means of linear di-
Table 1. Baseline patient characteristics
Controls Hypercholes- p
terolaemics
No. 10 9
Age 25±3 years 54±8 years <0.0001
Gender (m/f) 10/0 7/2
Cholesterol
Total cholesterol 4.4±0.4 8.7±2.1 <0.0001
HDL 1.4±0.3 1.4±0.3 NS
Ratio (total chol./HDL) 3.2±0.5 6.7±2.9 <0.005
LDL 2.6±0.5 6.0±1.7 <0.0001
Triglycerides 0.9±0.3 2.8±1.5 <0.005
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mension reduction of the dynamic sinograms as previously de-
scribed [13]. Regions of interest were drawn within the left ven-
tricular cavity and myocardium on consecutive image planes and
projected onto the dynamic 15O-water images to generate blood
time-activity curves. These curves were fitted to a single tissue
compartment tracer kinetic model to give values of regional and
global MBF (ml min−1 g−1) [4, 13, 14]. To account for the varia-
bility of coronary driving pressure, coronary resistance (mmHg ml−1
min−1 g−1) was also calculated as the ratio of mean arterial pres-
sure to MBF at rest, during adenosine infusion and after bicycle
stress [10, 15].
Flow reserve utilisation
Adenosine-induced hyperaemic MBF is considered to represent
(near) maximal flow. Flow reserve utilisation was calculated for
each subject as the ratio of exercise-induced to adenosine-induced
hyperaemic MBF and expressed as percent to indicate how much
of the maximal (adenosine-induced) hyperaemia can by achieved
by bicycle exercise. This index is comparable in different circum-
stances if external cardiac workload (rate–pressure product, RPP)
remains the same. Flow reserve utilisation represented the primary
endpoint of the study. A concept of flow reserve utilisation has
been previously proposed by Zeiher et al. [16]. In their study,
however, they assessed the capacity of the coronary system to in-
crease MBF in response to acetylcholine. Thus, the acetylcholine
dose–response relation was expressed as relative proportion of the
maximally obtainable coronary MBF response to papaverine.
Preparation of tetrahydrobiopterin (BH4)
A sodium bicarbonate-buffered solution of 10 mg kg−1 of (6R)-
5,6,7,8-tetrahydro-L-biopterin-dihydrochloride (BH4, Dr B. Schir-
cks Laboratories, Jona, Switzerland) was prepared as previously
described [11] in a total volume of 10 ml immediately before use
and diluted with 0.9% sodium chloride to a total volume of 50 ml.
The sterilely filtered, clear, colourless solution was infused into a
peripheral vein of the forearm using a pump at a constant flow of
99.9 ml h−1.
Statistical analysis
Data are reported as mean values ± standard deviation (SD) if not
otherwise stated. Intergroup comparisons of haemodynamic and
PET data at rest and during both stress modalities were carried out
by a two-way analysis of variance (ANOVA) for repeated mea-
surements, followed by the Scheffé F test when the ANOVA test
was significant (p<0.05).
Results
None of our subjects experienced adverse effects from
adenosine.
Haemodynamics
Resting heart rate (beats per minute) was slightly higher
after BH4 infusion in hypercholesterolaemic subjects
(65±10 vs 70±9, p<0.005) whereas it was unchanged in
control subjects (68±10 vs 70±9, NS). After BH4 infu-
sion, diastolic blood pressure (mmHg) increased signifi-
cantly at rest (68±15 vs 76±13, p<0.05) and during aden-
osine (66±13 vs 76±9, p<0.05) in controls but remained
unchanged in hypercholesterolaemic subjects (rest:
64±13 vs 70±11, NS; adenosine: 61±9 vs 67±5, NS). All
the other haemodynamic parameters were similar before
and after BH4 for all study conditions in controls and in
hypercholesterolaemic subjects, including the post-exer-
cise period (values averaged over 4 min) during which
MBF measurement was performed (Table 2). Further-
Table 2. Haemodynamics
Rest Adenosine Exercisea
Baseline BH4 p Baseline BH4 p Baseline BH4 p
Controls (n=10)
SBP 125±11 123±13 NS 133±11 134±11 NS 129±11 135±10 NS
DBP 68±15 76±13 <0.05 66±13 76±9 <0.05 72±9 78±8 NS
MAP 87±13 92±12 NS 89±12 95±7 NS 91±9 97±6 NS
HR 68±10 70±9 NS 93±14 97±16 <0.05 99±15 98±17 NS
RPP 8,483±1,381 8,634±1,901 NS 12,422±2,411 13,039±2,766 NS 12,699±1,967 13,652±2,236 NS
Hypercholesterolaemics (n=9)
SBP 139±16 137±12 NS 142±14 143±10 NS 141±18 147±10 NS
DBP 64±13 70±11 NS 61±9 67±5 NS 66±12 69±11 NS
MAP 89±13 92±11 NS 88±10 92±6 NS 91±14 92±6 NS
HR 65±10 70±9 <0.005 85±15 89±12 NS 86±16 85±15 NS
RPP 9,104±2,225 9,608±1,636 NS 12,052±2,185 11,210±4,437 NS 11,429±1,941 11,623±1,407 NS
SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, HR heart rate, RPP rate–pressure product
a Haemodynamic values immediately post exercise (averaged over 4 min).
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more, RPP during maximal bicycle exercise stress was
not affected by BH4 in controls (26,544±4,929 vs
25,197±5,188, NS) or in hypercholesterolaemic subjects
(23,774±4,566 vs 24,005±6,424, NS). RPP values did
not differ between the two groups, confirming similar
workload during exercise and allowing meaningful com-
parison of MBF between the two groups, particularly in
view of age-related differences in exercise performance.
MBF, coronary resistance and flow reserve utilisation
Values for repeat measurements of MBF were 1.16±
0.38 vs 1.15±0.31 ml min−1 g−1 at rest, 2.92±1.11 vs
2.69±0.69 ml min−1 g−1 during adenosine, and 2.12±
0.32 vs 1.99±0.45 ml min−1 g−1 after exercise. The re-
spective mean differences were not significant (−2% for
rest, −5% for exercise, −12% for adenosine). Values of
mean MBF and CFR utilisation before and after BH4 are
reported in Table 3. Individual values of hypercholes-
terolaemic subjects are given in Fig. 1. Resting and
adenosine-induced hyperaemic MBF were not affected
by BH4 either in controls or in hypercholesterolaemic
subjects. By contrast, MBF immediately after exercise
was significantly increased by BH4 infusion both in con-
trols (2.96±0.58 to 3.41±0.73 ml min−1 g−1, p<0.05) and
in hypercholesterolaemic subjects (2.47±0.78 to 2.70±
0.72 ml min−1 g−1, p<0.01).
Coronary resistance was not affected by BH4 in ei-
ther group at rest or during adenosine while it de-
creased by 15% after bicycle exercise in hypercholes-
terolaemic subjects (from 44 to 37 mmHg ml−1 min−1
g−1) but only by 8% in controls (from 31 to
29 mmHg ml−1 min−1 g−1).
Fig. 1. Individual values of
MBF and flow reserve utilisa-
tion are given for hypercholes-
terolaemic subjects before and
after BH4
Table 3. MBF and coronary flow reserve utilisation
Controls Hypercholesterolaemics
Baseline BH4 p Baseline BH4 p
MBF rest (ml min−1 g−1) 1.33±0.42 1.38±0.37 NS 1.46±0.18 1.42±0.27 NS
MBF adenosine (ml min−1 g−1) 4.52±1.10 4.85±0.45 NS 4.86±1.18 4.53±0.93 NS
MBF bicycle (ml min−1 g−1) 2.96±0.58 3.41±0.73 <0.05 2.47±0.78 2.70±0.72 <0.01
CFR utilisation (%) 70±17 71±19 NS 53±15 66±14 <0.05
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BH4 had no influence on flow reserve utilisation in
controls (70±17% vs 71±19%, p=NS for baseline versus
BH4 infusion). Compared with controls, flow reserve
utilisation was significantly lower in hypercholestero-
laemic subjects at baseline (53±15%; p<0.05 vs controls)
and increased significantly after BH4 infusion (66±14%,
p<0.05 vs baseline), approximating values similar to
controls (p=NS vs controls) (Fig. 2).
Discussion
This study demonstrates that in hypercholesterolaemia,
flow reserve utilisation after physical exercise is signifi-
cantly reduced compared with that in controls but is
nearly restored after BH4 infusion. BH4 increased micro-
circulatory response to physical exercise, which is
known to activate eNOS, but not to the endothelium-in-
dependent vasodilator adenosine. While previous studies
have shown a favourable effect of BH4 on conductance
arteries of the peripheral circulation [7] and epicardial
arteries [8] of subjects with hypercholesterolaemia, our
data extend these findings to the coronary microcircula-
tion and the regulation of MBF. Our data show that CFR
utilisation is significantly impaired in hypercholestero-
laemia, but restored after BH4 infusion.
In agreement with our previous results, we found
changes in MBF after BH4 without concomitant haemo-
dynamic changes. Although non-invasive arterial blood
pressure monitoring may not be the most sensitive meth-
od for detection of subtle peripheral vasodilatation, the
present data indicate that BH4 at the dose of 10 mg kg−1
has no peripheral vasodilating effect. This suggests ei-
ther a lower functional BH4 concentration in coronary
endothelial cells or a greater susceptibility of the coro-
nary circulation to BH4 as compared with the systemic
vascular bed. When defining all subjects with an in-
crease in flow reserve utilisation of 10% or more as re-
sponders, none of the healthy volunteers was a respon-
der, while six of the nine hypercholesterolaemic subjects
were responders. Among the hypercholesterolaemic sub-
jects, the non-responders tended to have the highest lipid
values, potentially indicating that the BH4 supplementa-
tion at the provided dose was insufficient. Due to the
limited numbers in this subpopulation, however, such a
statement remains speculative.
Several pharmacological agents have been proposed
to study the role of the endothelium of normal and ste-
notic coronary arteries, namely serotonin, noradrenaline,
vasopressin, adenosine, papaverine or acetylcholine [17].
In comparison with most previous studies, a different ap-
proach was used in the present study to induce coronary
vasodilation, namely dynamic bicycle exercise—a pow-
erful predictor of outcome and mortality as recently con-
firmed in a large long-term trial [18]. The effect of exer-
cise on coronary vasomotion is probably more complex
than that of a single pharmacological agent. A pharma-
cological stimulus alone may have been of limited value
in the assessment of the coronary microcirculatory func-
tion. However, very few reports in the literature deal
with the use of physical exercise in PET [19–21] and
only recently has its repeatability been documented in
healthy volunteers [9]. In this study, we have provided
the repeatability of the measurements for hypercholes-
terolaemic subjects. The mean differences between the
two repeat measurements were 2%, −5% and −12% for
rest, exercise and adenosine, respectively, comparing
well with the values reported in the literature by us [9,
14] and others [22].
Seiler et al. [23] have reported that exercise-induced
endothelium-mediated vasodilation of angiographically
smooth coronary arteries is inversely related to serum
cholesterol as well as LDL cholesterol levels. The pres-
ent study is the first to use physical exercise and PET
MBF measurement to document the impact of hyper-
cholesterolaemia (and of BH4 supplementation) on the
coronary circulation.
Endothelium-independent and -dependent 
coronary hyperaemic response
The vasodilator effect of adenosine has been generally re-
ported to be mainly based on the direct stimulation of
Fig. 2. Flow reserve utilisation
at baseline and after BH4 infu-
sion in controls and hyper-
cholesterolaemics. As RPP was
almost identical before and af-
ter BH4, the changes are not
due to changes in cardiac work
but indicate improved endothe-
lial function
A2A adenosine receptors on vascular smooth cells. There-
fore, adenosine has frequently been used to evaluate en-
dothelium-independent vasodilation [24]. Recently, it has
been appreciated that adenosine acts in part as an endo-
thelium-dependent vasodilator, although a large propor-
tion of its action is endothelium independent [6]. We used
adenosine as a stimulus because it induces (near) maxi-
mal hyperaemia and, thus, allows comparison of exer-
cise-induced hyperaemia with the maximal MBF achiev-
able in each individual subject. This strategy was chosen
to allow differentiation between endothelial-dependent
(bicycle exercise) and predominantly endothelial-inde-
pendent (adenosine) hyperaemia. The flow reserve utili-
sation indicates how much of the maximal available hy-
peraemic MBF can be utilised during physical exercise.
Exercise stress is a complex stimulus of MBF, but
probably more comparable to daily physical activities
[25–28] than other stimuli such as pharmacological va-
sodilators or pacing stress. Both intracoronary acetylcho-
line [29] and dynamic exercise [3, 25, 28] have been
shown to constrict the coronary arteries in the presence
of an atherosclerotic lesion but to dilate normal coronary
vessels. Thus, physical exercise seems to be a reliable
tool for testing coronary endothelial function. In particu-
lar, physical exercise stimulates eNOS activity in a shear
stress-dependent manner [27, 30, 31]. In conjunction
with PET this provides a new non-invasive tool for as-
sessing physiological mechanisms of coronary vasomo-
tor control, which regulate absolute quantitative MBF.
Exercise-induced hyperaemic MBF may result not
only from an increase in oxygen demand producing more
metabolic vasodilation, but also from either direct stimu-
lation of α2-adrenoceptors in intact endothelial cells and
the release of NO [32] or direct β2-adrenoceptor-mediat-
ed dilation of coronary arterioles by noradrenaline [33].
Endothelial integrity seems to play a major role in exer-
cise-induced hyperaemia as early stages of endothelial
dysfunction and atherosclerosis already impair coronary
dilator responses. In fact, in angiographically normal
epicardial vessels, exercise-induced vasodilation is atten-
uated or completely blunted in the presence of hyperten-
sion or hypercholesterolaemia [3, 28, 30, 34].
Both stimuli, i.e. adenosine and bicycle stress, induce
a hyperaemic MBF response mediated via a complex
combination of sympathetic efferents [15], adenosine re-
ceptor activation and other mechanisms. However, exer-
cise-induced hyperaemic MBF is predominantly endo-
thelium dependent [3, 28, 30, 34] whereas adenosine-in-
duced hyperaemic MBF is predominantly endothelium
independent [24]. In order to cancel out the non-endothe-
lial-dependent mechanisms and to most selectively as-
sess endothelial function, we therefore expressed the ex-
ercise-induced hyperaemic MBF in relation to the adeno-
sine-induced response, proposing (percent) flow reserve
utilisation as an index of endothelial function.
The observed increase in exercise MBF in healthy
volunteers could be due to a direct unspecific anti-oxi-
dant effect of BH4 similar to that of vitamin C, which
has been shown to improve endothelial function in heal-
thy volunteers by protecting NO from inactivation by
oxygen free radicals. Alternatively, BH4 may have im-
proved endothelial-dependent vasodilation specifically
through the increased production of NO. This confirms a
recent report on further improvement of endothelial
function by aerobic exercise in healthy volunteers who
do not have endothelial dysfunction [35].
BH4 and flow reserve utilisation
Flow reserve utilisation was significantly lower in hyper-
cholesterolaemic than in control subjects but was re-
stored after BH4 infusion. Under high-flow conditions
such as bicycle exercise stress, BH4 supplementation
seems to have a favourable effect by increasing the exer-
cise-induced flow response, possibly by counteracting
short-term relative substrate depletion. Alternatively, re-
duced NO bioavailability may reflect increased break-
down by superoxide anions. NOS itself may be a source
of superoxide anion production at suboptimal concentra-
tions of BH4.
Study limitations
Data acquisition was obtained in the immediate post-ex-
ercise period when the cardiac power output is consider-
ably decreased and when flow is expected to fall rapidly.
These suboptimal conditions were chosen to avoid ex-
cessive motion artefact during scanning [9, 10]. As a
consequence, we could not assess maximal flow during
peak exercise but rather assessed the average flow during
the first minutes of recovery. This seems a potential limi-
tation of our study as the maximal impact of BH4 is an-
ticipated during high-flow conditions with maximal
shear stress such as peak flow. Nevertheless, we found
that BH4 induced a significant improvement in microcir-
culatory dysfunction under submaximal flow conditions,
which strengthens our result. The present protocol pro-
vides the response to physical exercise, which is repro-
ducible [9] and is appropriate for study of the influence
of interventions on exercise-induced (endothelium-de-
pendent) CFR [10].
Hypercholesterolaemic subjects were older than con-
trols. This difference may potentially have hampered the
comparability of the two groups’ flow reserve as the
flow reserve has been shown to decrease after the age of
60 [36], though mainly due to an increase in basal flow
[37]. By contrast, however, maximal hyperaemic re-
sponse decreases only after the age of 70 years [38], and
this age-related effect is irrelevant to our study as none
of our patients was older than 70 years. The use of every
subject as his or her own control further strengthens our
results, although theoretically it cannot be entirely ex-
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cluded that at different ages BH4 may exert differential
unspecific anti-oxidant effects.
RPP was almost identical before and after BH4 under
the different conditions, indicating that the improvement in
flow reserve utilisation was not due to changes in cardiac
work but reflected improved endothelial function in hyper-
cholesterolaemic subjects at a workload targeted to 70% of
the predicted workload according to the study protocol.
As none of the subjects underwent coronary angiogra-
phy, subclinical CAD cannot be ruled out with certainty.
However, the clinical risk for coronary artery disease was
assessed as low before enrolment. In addition, it has recent-
ly been demonstrated that even in patients with mild CAD,
flow assessed with PET can still be used to evaluate the
functional response of the coronary artery circulation [2].
Conclusion
Acute administration of BH4 seems to restore CFR utili-
sation in hypercholesterolaemic subjects, suggesting that
BH4 deficiency may contribute to coronary microcircula-
tory dysfunction in hypercholesterolaemia.
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